The development of a cost-effective and stable single-administration vaccine (SAV) formulation to achieve vaccination regimen reduction

开发具有成本效益且稳定的单次给药疫苗（SAV）制剂，以实现疫苗接种方案的减少

• 批准号: 2431779
• 金额: --
• 依托单位: Aston University
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2431779
• 关键词: development; cost; effective; stable; single

Both the evolution of the pharmaceutical industry and the Children's Vaccine Initiative launched by WHO led to the genesis and development of the idea of single administration vaccines (SAVs). SAVs are controlled release formulations aiming to provide prime and booster doses in a single shot. Despite continuing efforts during the last forty years, there is no single administration vaccine formulation on the market yet. To reduce the formulation cost and enable scalability, a three fluid-nozzle spray dryer will be used. Such techniques can provide double encapsulation to address the two major challenges (antigen stability, release mechanism) in a single step. The aim is to create a novel platform that can be loaded with antigens capable of generating non-inferior immunogenicity to conventional vaccines.

制药业的发展和世卫组织发起的儿童疫苗倡议导致了单次接种疫苗（SAV）概念的产生和发展。SAV是控释制剂，旨在单次注射中提供初免和加强剂量。尽管在过去的四十年中不断努力，但市场上还没有单次施用的疫苗制剂。为了降低制剂成本并实现可扩展性，将使用三流体喷嘴喷雾干燥器。这样的技术可以提供双重包封以在单个步骤中解决两个主要挑战（抗原稳定性、释放机制）。其目的是创建一种新型平台，该平台可以装载能够产生非劣于常规疫苗的免疫原性的抗原。